1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
December 2025 in “Journal of Inflammation Research” Improving education, training, and access to affordable treatments is crucial for better managing inflammatory skin diseases in Latin America.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient care and education.